ClinicalTrials.gg
CompletedNCT05913544SINTYAUpdated Nov 13, 2026

Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

An interventional study of SINTYA in Borderline Personality Disorder, sponsored by Centre Hospitalier Universitaire de Nīmes. Completed at 1 site in France. Open to participants aged 16 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
16 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Borderline Personality Disorder with a site in France — 12 open to participants now, 13 under way, none of them phase 3. Borderline Personality Disorder · France.

Enrollment
12th of 24
74 · median 72
Started
2023
with 2 others
No phase
20 of 32
9 open now
Registered
23rd of 32
by date
Lead sponsor
2 of 32
Centre Hospitalier Universitaire de Nīmes

Among the 32 studies in Borderline Personality Disorder with a site in France, this one is the 12th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2023, is one of 20 with no phase, and was the 23rd registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

12 of the 32 studies in Borderline Personality Disorder with a site in France are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 16 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Borderline Personality Disorder with a site in France, or all of them as a file.
02

Study summary

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

03

Conditions studied

  • Borderline Personality Disorder
04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of BPD according to criteria and BPQ-80 scale.
  • High BPD severity level: ZAN-BPD (score ≥ 18/36).
  • Understand, write and read French.
  • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
  • Have signed the .
  • For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate.
  • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
  • Intelligence quotient \< 70.
  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
  • Previous or current participation in specific psychotherapy for BPD.
  • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
  • Inclusion in another study including psychotherapy for the duration of the study.
  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
  • Subject in period of exclusion from another research protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    SINTYA group

    Other: SINTYA

  • No intervention
    Control

Interventions

  • OtherSINTYA

    10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

06

What researchers measure

Primary outcomes

  1. Variation in explicit impulsivity between groups

    UPPS-S (Impulsive Behavior Scale Short version score)

    Time frame: Baseline

  2. Variation in explicit impulsivity between groups

    UPPS-S (Impulsive Behavior Scale Short version score)

    Time frame: Month 4

Secondary outcomes

  1. Variation in explicit impulsivity between groups

    UPPS-S (Impulsive Behavior Scale Short version score)

    Time frame: Month 7

  2. Variation in impulsiveness between groups

    Barratt Impulsiveness Scale (BIS-11) (score out of 120)

    Time frame: Baseline

  3. Variation in impulsiveness between groups

    Barratt Impulsiveness Scale (BIS-11) (score out of 120)

    Time frame: Month 4

  4. Variation in impulsiveness between groups

    Barratt Impulsiveness Scale (BIS-11) (score out of 120)

    Time frame: Month 7

  5. BPD severity level between groups

    Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

    Time frame: Baseline

  6. BPD severity level between groups

    Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

    Time frame: Month 4

  7. BPD severity level between groups

    Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

    Time frame: Month 7

  8. Emotional regulation capacities between groups

    Difficulties in Emotion Regulation Scale (DERS-18)

    Time frame: Baseline

  9. Emotional regulation capacities between groups

    Difficulties in Emotion Regulation Scale (DERS-18)

    Time frame: Month 4

  10. Emotional regulation capacities between groups

    Difficulties in Emotion Regulation Scale (DERS-18)

    Time frame: Month 7

  11. Dissociative symptoms between groups

    Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

    Time frame: Baseline

  12. Dissociative symptoms between groups

    Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

    Time frame: Month 4

  13. Dissociative symptoms between groups

    Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

    Time frame: Month 7

  14. Aggression between groups

    Aggression Questionnaire (AQ-12)

    Time frame: Baseline

  15. Aggression between groups

    Aggression Questionnaire (AQ-12)

    Time frame: Month 4

  16. Aggression between groups

    Aggression Questionnaire (AQ-12)

    Time frame: Month 7

  17. Ruminations between groups

    Rumination Reflection Questionnaire (RRQ)

    Time frame: Baseline

  18. Ruminations between groups

    Rumination Reflection Questionnaire (RRQ)

    Time frame: Month 4

  19. Ruminations between groups

    Rumination Reflection Questionnaire (RRQ)

    Time frame: Month 7

  20. Number of self-destructive behaviors between groups

    Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

    Time frame: Baseline

  21. Number of self-destructive behaviors between groups

    Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

    Time frame: Month 4

  22. Number of self-destructive behaviors between groups

    Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

    Time frame: Month 7

  23. Number of impulsive behaviors between groups

    Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

    Time frame: Baseline

  24. Number of impulsive behaviors between groups

    Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

    Time frame: Month 4

  25. Number of impulsive behaviors between groups

    Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

    Time frame: Month 7

  26. Level of suicide risk between groups

    Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Baseline

  27. Level of suicide risk between groups

    Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Month 4

  28. Level of suicide risk between groups

    Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Month 7

  29. Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups

    Information taken from patient medical file

    Time frame: 12 Months prior to inclusion

  30. Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups

    Information taken from patient medical file

    Time frame: Baseline

  31. Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups

    Information taken from patient medical file

    Time frame: Month 4

  32. Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups

    Information taken from patient medical file

    Time frame: Month 7

  33. Psychosocial functioning between groups

    Functional Assessment Staging Tool (FAST)

    Time frame: Baseline

  34. Psychosocial functioning between groups

    Functional Assessment Staging Tool (FAST)

    Time frame: Month 4

  35. Psychosocial functioning between groups

    Functional Assessment Staging Tool (FAST)

    Time frame: Month 7

  36. Implicit impulsivity between groups

    Continuous Performance Test (CPT)

    Time frame: Baseline

  37. Implicit impulsivity between groups

    Continuous Performance Test (CPT)

    Time frame: Month 4

  38. Implicit impulsivity between groups

    Continuous Performance Test (CPT)

    Time frame: Month 7

  39. Neurocognitive evaluation of implicit impulsivity between groups

    Emotional Stroop (SE) customized to the study

    Time frame: Baseline

  40. Neurocognitive evaluation of implicit impulsivity between groups

    Emotional Stroop (SE) customized to the study

    Time frame: Month 4

  41. Neurocognitive evaluation of implicit impulsivity between groups

    Emotional Stroop (SE) customized to the study

    Time frame: Month 7

  42. Risk taking between groups

    Balloon Analogue Risk Task (BART)

    Time frame: Baseline

  43. Risk taking between groups

    Balloon Analogue Risk Task (BART)

    Time frame: Month 4

  44. Risk taking between groups

    Balloon Analogue Risk Task (BART)

    Time frame: Month 7

  45. Decision making under risk conditions between groups

    Game Dice Task (GDT)

    Time frame: Baseline

  46. Decision making under risk conditions between groups

    Game Dice Task (GDT)

    Time frame: Month 4

  47. Decision making under risk conditions between groups

    Game Dice Task (GDT)

    Time frame: Month 7

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Upon publication

Access criteria: The IPD will be made available to other researchers upon reasonable request to the corresponding author

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Sep 2025, 22 months.

Of 106 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's 22 months is below that.

Counting every sponsor, half of 108 studies reached it within 35 months; a quarter within 24 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2026 → Sep 2025 and completion Sep 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jun 22, 2023
StartActual
Nov 8, 2023
Primary completionActual
Sep 13, 2025was Sep 2026
CompletionActual
Dec 22, 2025was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Sep 2026→Sep 13, 2025 (actual)
Nov 13, 2026
Study completion
Sep 2026→Dec 22, 2025 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Sep 2026→Sep 13, 2025 (now actual)
    Study completion Sep 2026→Dec 22, 2025 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05913544
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Nov 8, 2023
Primary completion
Sep 13, 2025
Completion
Dec 22, 2025
Last update
Nov 13, 2026

Study contacts

Clémentine Estric
principal investigator · CHU de Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion